R&D grant and tax rebate are very different. At current stage PRR cannot enjoy the 45% tax rebate simply because it has not generated positive EBIT yet, no tax paid = no rebate. But once the product goes commercialized, it will reduce the company’s tax significantly.
This will not benefit shareholders in the tax perspective, but you can calculate it as a discount of SP in the long run if you buy it today.
Note the accounting treatment for R (research) and D (development) are very different.
And yes, this increases the possibility of PRR become a takeover target by those biotech giants in earlier stage in order to save their income tax and improve cash flow.
- Forums
- ASX - By Stock
- IMM
- interesting article from mergermarket
interesting article from mergermarket, page-8
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
Add IMM (ASX) to my watchlist
|
|||||
Last
30.8¢ |
Change
-0.033(9.56%) |
Mkt cap ! $450.3M |
Open | High | Low | Value | Volume |
33.0¢ | 33.0¢ | 30.5¢ | $676.2K | 2.131M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 160828 | 30.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 41440 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 160828 | 0.305 |
17 | 242715 | 0.300 |
8 | 167447 | 0.295 |
18 | 492797 | 0.290 |
15 | 542528 | 0.285 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 41440 | 10 |
0.315 | 201076 | 11 |
0.320 | 180832 | 6 |
0.325 | 104240 | 5 |
0.330 | 78921 | 7 |
Last trade - 11.36am 05/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |